A phase 2 prospective, single-arm, single-center trial of neoadjuvant SOX combined with cadonilimab (AK104) for PD-L1 negative upper GC/GEJC patients
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Cadonilimab (Primary) ; Gimeracil/oteracil/tegafur; Oxaliplatin
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 13 Jan 2025 New trial record